HOXD13 and autoimmune disease: Studies found that sPD-1/sPD-L1 expression is upregulated in patients with autoimmune disease compared to the control group while a downregulation was observed after treatment, which suggests that sPD-1 can resist the inhibitory effect of PD-1 on T-cells, indirectly promoting immune responses [227–231].